Lyell Immunopharma, Inc. Other Comprehensive Income (Loss), Net of Tax
Lyell Immunopharma, Inc. (LYEL) reported Other Comprehensive Income (Loss), Net of Tax of -$49.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-03-12
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $41.00K.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $144.00K, a 87.55% decline year-over-year.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$101.00K, a 1542.86% decline year-over-year.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-03-31 was -$133.00K.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$49.00K, a 112.73% decline from fiscal 2024.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $385.00K, a 94.87% decline from fiscal 2023.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $7.50M.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$5.98M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $185.00K derived: sum of 2 quarters · filed 2026-03-12 | $84.00K derived: sum of 3 quarters · filed 2026-03-12 | -$49.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $144.00K 10-Q · filed 2025-11-12 | $43.00K derived: sum of 2 quarters · filed 2025-11-12 | -$90.00K 10-Q · filed 2025-11-12 | -$559.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | -$101.00K 10-Q · filed 2025-08-12 | -$234.00K 10-Q · filed 2025-08-12 | -$703.00K derived: sum of 3 quarters · filed 2026-03-12 | $454.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | -$133.00K 10-Q · filed 2025-05-13 | -$602.00K derived: sum of 2 quarters · filed 2026-03-12 | $555.00K derived: sum of 3 quarters · filed 2026-03-12 | $562.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | -$469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $688.00K derived: sum of 2 quarters · filed 2026-03-12 | $695.00K derived: sum of 3 quarters · filed 2026-03-12 | $385.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.16M 10-Q · filed 2025-11-12 | $1.16M derived: sum of 2 quarters · filed 2025-11-12 | $854.00K 10-Q · filed 2025-11-12 | $1.94M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $7.00K 10-Q · filed 2025-08-12 | -$303.00K 10-Q · filed 2025-08-12 | $784.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.98M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$310.00K 10-Q · filed 2025-05-13 | $777.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.98M derived: sum of 3 quarters · filed 2026-03-12 | $3.48M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.29M derived: sum of 2 quarters · filed 2026-03-12 | $3.79M derived: sum of 3 quarters · filed 2026-03-12 | $7.50M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.20M 10-Q · filed 2024-11-07 | $2.70M derived: sum of 2 quarters · filed 2024-11-07 | $6.42M 10-Q · filed 2024-11-07 | $8.81M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-07 | $5.22M 10-Q · filed 2024-08-07 | $7.62M derived: sum of 3 quarters · filed 2025-03-11 | $5.97M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $3.72M 10-Q · filed 2024-05-06 | $6.12M derived: sum of 2 quarters · filed 2025-03-11 | $4.47M derived: sum of 3 quarters · filed 2025-03-11 | $2.72M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $752.00K derived: sum of 2 quarters · filed 2025-03-11 | -$999.00K derived: sum of 3 quarters · filed 2025-03-11 | -$5.98M 10-K · filed 2025-03-11 |
| 2022-09-30 | -$1.65M 10-Q · filed 2023-11-07 | -$3.40M derived: sum of 2 quarters · filed 2023-11-07 | -$8.37M 10-Q · filed 2023-11-07 | -$9.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$1.75M 10-Q · filed 2023-08-08 | -$6.73M 10-Q · filed 2023-08-08 | -$8.29M derived: sum of 3 quarters · filed 2024-02-28 | -$8.42M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$4.98M 10-Q · filed 2023-05-04 | -$6.54M derived: sum of 2 quarters · filed 2024-02-28 | -$6.67M derived: sum of 3 quarters · filed 2024-02-28 | -$6.76M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.70M derived: sum of 2 quarters · filed 2024-02-28 | -$1.79M derived: sum of 3 quarters · filed 2024-02-28 | -$1.88M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$138.00K 10-Q · filed 2022-11-08 | -$228.00K derived: sum of 2 quarters · filed 2022-11-08 | -$321.00K 10-Q · filed 2022-11-08 | -$658.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$90.00K 10-Q · filed 2022-08-04 | -$183.00K 10-Q · filed 2022-08-04 | -$520.00K derived: sum of 3 quarters · filed 2023-02-28 | -$1.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$93.00K 10-Q · filed 2022-05-10 | -$430.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.03M derived: sum of 3 quarters · filed 2023-02-28 | -$923.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$935.00K derived: sum of 2 quarters · filed 2023-02-28 | -$830.00K derived: sum of 3 quarters · filed 2023-02-28 | -$198.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$598.00K 10-Q · filed 2021-11-12 | -$493.00K derived: sum of 2 quarters · filed 2021-11-12 | $139.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $105.00K 10-Q · filed 2021-08-12 | $737.00K 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $454.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |